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1. Introduction 
Vitiligo is largely classified into segmental and non-segmental types (Table 1).1 This 
classification is based on the original report by Koga in 1977.2 Koga proposed that vitiligo in 
a non-dermatomal distribution be referred to as Type A and vitiligo in a dermatomal 
distribution be Type B, the latter of which corresponds to what is known today as segmental 
vitiligo (SV). Since then, the distinctive characteristics of SV have been described.3-6 
Recently, it was proposed that vitiligo be classified into four major types: segmental, non-
segmental, mixed, and unclassified.7 
The incidence of SV is not well-established because different investigators report variable 
percentages of patients having SV. El-Mofty et al reported that only 5% of patients with vitiligo 
had the segmental type.8 Koga and Tango described that in their population, 27.9% had SV.3 
Several studies in Korea revealed the prevalence of SV to range from 5.5% to 29.6%.4,9,10  
The typical lesion of SV is not significantly different from that of NSV. Both can initially 
appear as focal vitiligo, which involves a small area.11 However, SV has a distinct natural 
history and unique clinical features.1,3,4 In addition, SV shows different therapeutic 
characteristics when compared with NSV.1,12 
SV can appear at any age, but the majority of cases occur early in life between the ages of 5 
and 30 years old. Koga and Tango reported that 82% of type B vitiligo (SV) patients noticed 
their first depigmented patches before the age of 30.3 In the pivotal SV study by Hann and 
Lee, the mean age of onset was 15.6 years, and SV developed before 10 years of age in 41% 
of cases, and before 30 years of age in 87%.4 In our study, the mean age of onset was 19.8 
years; 32% of SV started before 10 years of age and 62% before 20 years of age.6 
SV typically presents with unilateral involvement of depigmented macules surrounded by 
normal skin. The color of the macules is usually white and more distinguishable with 
Wood’s light examination. However, macules may have a more irregular border and less 
homogeneous pattern of pigment loss than NSV.11 Trichrome vitiligo, which is characterized 
by both depigmented and hypopigmented macules, is reported in SV.13  
SV shows a quasi-dermatomal mode of distribution, but seems to be different from the pattern 
of herpes zoster. SV often involves a segment that includes the parts of several dermatomes 
and may at times, go over the midline partially. Some cases may involve lines or large bands 
consistent with Blaschko’s lines.14,15 There is no preferential distribution between right and left 
sides of the body. Very rarely, SV involves two or more different segments with ipsilateral or 
contralateral distribution. Lee and Hann reported that 5 of 240 SV cases showed bilateral SV 
on the same or different dermatomes that appeared on both sides of the body.16  
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The face is the most common site of SV regardless of gender (Figure 1). According to the 
Hann and Lee study, 51% of SV involved the face, 25% the trunk (Figure 2), and 11% the 
extremities. In our own study, 54% of SV involved only the face.4 An additional 17% had 
both face and neck involvement of SV (Figure 3).6  
 
 
Fig. 1. Segmental vitiligo on the face. 
  
Fig. 2. Segmental vitiligo on the abdomen. 
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Fig. 3. Segmental vitiligo on the face and neck. 
Hann et al proposed the original classification of the SV distribution of the face.17 This was 
revised to include 6 types depending on pattern and area of involvement.15 This 
classification may be valuable for certain aspects of prognosis, such as the likely degree and 
path of lesional spread. 
SV is often associated with the occurrence of white hair (i.e., poliosis, leukotrichia) in 
lesional skin. SV tends to involve the hair compartment soon after onset compared to NSV.1 
Hann and Lee reported that poliosis was found in 49% of 208 patients with SV.4 The 
eyebrow (Figure 4) and eyelashes commonly show white hair and other hair-bearing sites 
including the scalp, pubis, and axilla can be involved. However, it is very difficult to notice 
the presence of white hairs on other areas of the body with the naked eye because the hairs 
consist of tiny, thin vellus hairs. We examined 82 patients for the presence of leukotrichia in 
SV lesions using a digital portable microscope. All of the patients demonstrated leukotrichia 
independent of age and disease duration (Figure 5).6,18 The amount of white hair was 
variable. These results suggest that a very high percentage of patients with SV have 
associated leukotrichia. 
It has been reported that SV usually spreads within a segment in a short period of time and 
then tends to stop.3,4 However, in our own study, we observed 87 patients who had SV for 
mean of 29.5 months (maximum 150 months), 19 cases (21.8%) showed disease progression 4 
years after disease onset (2011 IPCC presentation). Therefore, more long-term follow-up 
data are needed in order to more accurately understand the natural course and the long-
term recurrence rate of SV. 
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Fig. 4. White hairs of the eyebrow in segmental vitiligo can be seen. 
 
 
 
Fig. 5. Leukotrichia in a segmental vitiligo lesion can be seen easily using portable digital 
microscopy (magnified 30x) 
It has been proposed that the rare instance of SV progresses into a generalized form, that 
this be called mixed vitiligo.19 However, this likely represents only the rare circumstance of 
concurrent SV and NSV rather than its own independent vitiligo type.  
SV is not usually accompanied by other autoimmune diseases contrary to NSV.1,3,8 However, 
Park et al reported that about 9.5% of SV cases were associated with other diseases20 and 
Hann et al described that 6.7% of 208 patients had an associated disease, including atopic 
dermatitis, halo nevus, thyroid disease, diabetes mellitus, and alopecia areata.4  
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Segmental Vitiligo Non-Segmental Vitiligo 
Often early age of onset Variable age of onset 
Usually unilateral Usually bilateral 
Is known to spread rapidly and stabilize in 
a few years* 
Usually chronic and progressive course 
Predictable course Unpredictable course 
Very high percentage of white hairs 
(leukotrichia) of lesional skin in early stage 
disease 
Variable percentage of white hairs 
(leukotrichia) of lesional skin 
Shows good response to autologous 
grafting 
Shows unpredictable results after 
autologous grafting 
Is not usually associated with autoimmune 
disease 
Is often associated with personal or family 
history of autoimmune disease 
*Long-term data is still warranted. 
Table 1. Comparison of Segmental Vitiligo and Non-Segmental Vitiligo 
2. Treatment of segmental vitiligo 
Segmental vitiligo (SV) is a distinct type of vitiligo in terms of its clinical features, natural 
course, and response to treatment, that make it distinguishable from non-segmental 
vitiligo (NSV).1,2 In SV, white macules are usually localized to one segment on only one 
side of the body, however, in NSV white macules can occur at any body location and 
disease activity tends to persist throughout the life of the patient. Thus, the course of SV is 
predictable while that of NSV is unpredictable. Treatment guidelines of SV may be easier 
to determine than those of NSV. 
Until now, many articles about vitiligo treatment have been published. However, many of 
these studies were not randomized, controlled, and double-blinded, but rather retrospective 
studies or case reports. In addition, many studies did not distinguish between the types of 
vitiligo or they did not provide demographic information about SV in detail. Thus, reliable 
publications about the treatment of SV are scarce. 
The treatment modalities for vitiligo largely consist of medical and surgical therapies.21 
Medical management includes topical corticosteroids and immunomodulators, and 
phototherapy such as narrow-band UVB (NB-UVB) and excimer laser. If medical treatment 
is unsatisfactory, surgical treatments such as autologous skin grafting may be considered. 
Taïeb and Picardo presented treatment guidelines for vitiligo in a review.1 
2.1 Topical corticosteroids 
Topical corticosteroids have been used for the treatment of vitiligo for decades. There have 
only been a few studies about the effects of topical corticosteroids in SV. 
Koga evaluated the effect of topical corticosteroids in vitiligo patients.2 In this study, only 
five patients with SV were included and received topical steroid therapy (0.12% 
betamethasone-17-valerate, 0.01% fluocinolone acetonide, or 0.1% triamcinolone acetonide 
cream or ointment) for a minimum of 2 months. However, no improvement was found in 
any of these patients. 
Khalid and Mujtaba treated forty SV patients with 0.05% clobetasol propionate cream twice 
daily.22 Therapy was interrupted every 6 weeks for a 2-week treatment-free period. Some 
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response was observed in the majority of patients (79%, 30 out of 38) and more than 50% 
repigmentation was observed in 34% (13) of patients. The best results were found on the 
face. Out of the 23 patients who presented within 1 year of SV onset, 11 (47.8%) showed 
more than 50% repigmentation; on the other hand, only two out of 15 (13.3%) patients who 
presented after one year of the onset of SV achieved the same degree of response. The side 
effects were mild skin atrophy in six patients, telangiectasias in four patients, and acneiform 
papules in eight patients. These results suggest that disease duration may be an important 
indicator of prognosis because most of the patients showing more than 50% repigmentation 
presented within one year of SV onset. 
2.2 Topical immunomodulators (calcineurin inhibitors) 
Several studies have demonstrated the efficacy of tacrolimus ointment and pimecrolimus 
cream in the treatment of vitiligo patients. However, most of them did not disclose the 
inclusion of SV. 
Silverberg et al assessed the efficacy of topical tacrolimus ointment in the treatment of 
childhood vitiligo.23 Fifty-seven patients were treated with tacrolimus ointment (0.03% or 
0.1%) once or twice daily for a minimum of three months. In their series, 37% of the patients 
had SV, most commonly of the head and/or neck. Among the SV patients, 86% responded 
to tacrolimus ointment, especially those with facial involvement (94%). One patient showed 
complete repigmentation on the chin and neck after eight weeks of summer sun exposure 
along with twice daily tacrolimus 0.03% ointment.  
Udompataikul et al evaluated the effectiveness of 0.1% tacrolimus ointment in 42 vitiligo 
patients, of whom eleven patients had SV.24  The overall response rate, defined as at least 
some evidence of repigmentation, was 76% and the response rate for SV was 77%.  
2.3 Phototherapy  
Phototherapy has been widely used for the treatment of vitiligo. However, most studies 
about phototherapy in vitiligo were performed in patients with NSV. 
1. NB-UVB  
Anbar et al evaluated the clinical response of vitiligo patients to NB-UVB. Their study 
included 150 patients with SV (10%) or NSV (90%).25 NB-UVB therapy was given twice 
weekly. In the NSV group, 48% of patients showed a marked response (more than 75% 
repigmentation) and 27% showed a moderate response (between 26% and 75% 
repigmentation). However, in the SV group, 92.3 % showed no more than a mild response 
(less than 25% repigmentation) to treatment regardless of the lesion site, and only 7.7% of 
SV patients showed a moderate response.  
NB-UVB microphototherapy uses a device that delivers a focused beam with wavelengths 
from 300 to 320 nanometers (nm) with a peak emission of 311 nm. Lotti et al evaluated the 
effectiveness of UVB microphototherapy for eight SV patients for six months.26 Five patients 
achieved normal pigmentation on more than 75% of their treated areas. 
2. PUVA 
Tallab et al evaluated the efficacy of systemic psoralen and ultraviolet A (PUVA) in the 
treatment of vitiligo retrospectively.27 Thirty-two patients with vitiligo were studied, 
including five patients with SV. All of the SV patients showed no or poor repigmentation. 
They concluded that SV was very resistant to PUVA therapy. 
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3. Excimer laser 
The 308 nm excimer laser has demonstrated promising efficacy and appealing side effect 
profile for localized vitiligo.28,29 Compared with conventional NB-UVB, excimer laser 
generally provides more rapid repigmentation in limited forms of vitiligo.  
Do et al performed a retrospective analysis to evaluate the treatment response to excimer 
laser in SV patients.30 Eighty patients with SV were included. Repigmentation was graded as: 
grade 0, no repigmentation; grade 1, 1–24%; grade 2, 25–49%; grade 3, 50–74%; grade 4, 75–
99%; grade 5, complete repigmentation. The mean grade of repigmentation was 2.3 after a 
mean of 20.6 months of treatment; 23.8% showed grade 4, 20% showed grade 3, and 56.2% 
showed grade 1–2 repigmentation. However, none of them achieved complete 
repigmentation. They observed that SV had a better repigmentation response rate when the 
excimer laser was used at earlier stages of the disease for longer treatment durations with 
high cumulative UV energy. However, the limitation of their study was that many patients 
received other concurrent treatments such as oral corticosteroids, topical steroids, or topical 
tacrolimus ointment during the study period. 
4. Miscellaneous Therapies 
We retrospectively evaluated the effect of phototherapy in nine patients with SV depending 
on the disease duration.31 All patients except one had SV for longer than two years when 
they started on a phototherapy regimen of PUVA, NB-UVB, or excimer laser. All patients 
showed a poor response to phototherapy irrespective of the type of phototherapy 
administered. Our results suggest that phototherapy is not helpful in long-duration SV.  
It has been reported that the combination of NB-UVB and tacrolimus ointment is effective in 
vitiligo.32 However, this combination treatment of NB-UVB and tacrolimus ointment in SV is 
limited to case reports. 
We presented two cases of recent onset SV that showed good or excellent response to 
targeted phototherapy (Dualight®) in combination with drug therapy.33 Our results suggest 
that SV can be improved with combination therapy if SV onset is recent, emphasizing that 
early treatment may be essential for this type of vitiligo. In addition, we reported a case of 
SV that showed a marked response to combination NB-UVB and 0.1% topical tacrolimus 
compared with 0.1% topical tacrolimus alone.34 This case suggests that combination therapy 
is necessary for SV.  
Low-energy helium-neon laser (632.8 nm) has applications in a variety of clinical conditions 
including vitiligo. Yu et al evaluated the efficacy of the helium-neon laser on thirty patients 
with SV on the head and/or neck.35 Marked repigmentation (more than 50%) was observed 
in 60% of patients. 
2.4 Surgical treatment 
Generally, surgical treatment is indicated for stable vitiligo that does not respond to medical 
treatment.36 Patients with SV are considered a good candidates for surgical treatment.21 
Although medical treatment is often helpful in SV, complete repigmentation is almost 
always difficult to obtain. Thus, surgical treatment is necessary for complete repigmentation 
in many cases of SV. Surgical treatment includes autologous epidermal grafting (Figure 6), 
mini-grafting, and transplantation of epidermal cell suspensions.21  
Gupta and Kumar analyzed a retrospective, uncontrolled case series and literature review of 
143 patients treated with epidermal grafting. They found that repigmentation success rates 
for generalized and segmental (including focal) vitiligo were 53 and 91%, respectively.37 
In epidermal grafting surgeries, oral corticosteroids may be a helpful adjunct. We reported 
that in a case of SV with failure to repigment with surgery alone, that response occurred 
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when oral corticosteroid was added to the grafting procedure.38 In addition, we also 
presented that achieving better results in SV may be contingent on combination therapy 
utilizing epidermal grafting with systemic corticosteroids.39  
SV may continue to spread even a few years after onset of disease. We presented a case of 
SV which continued to spread after epidermal grafting; the new lesions did not involve the 
area of previous epidermal grafting, but repeated epidermal grafting was successful.40 This 
case indicates that epidermal grafting can be useful for the treatment of SV although 
recurrence may arise. 
 
 
Fig. 6. Before (left) and after (right) epidermal grafting in segmental vitiligo. 
In vitiligo lesions with leukotrichia present, the possibility of repigmentation may be 
minimal or absent because the loss of hair melanocytes is usually permanent, and 
repigmentation may not occur even with medical treatment. We found that the majority of 
white hairs in SV may contribute to the lack of response to medical treatment and require 
surgical treatment such as epidermal grafting.6 
 
First-Line  
- Topical treatment (topical corticosteroids, calcineurin inhibitors) and narrow-band UVB 
(NB-UVB) therapy or targeted phototherapy (i.e., excimer laser) for at least 3 months. If 
there is treatment response, continue the regimen for 1 year.  
- If the majority of hairs in the lesional skin are white (leukotrichia), consider surgical 
treatment. 
Second-Line 
- Consider surgical treatment if medical treatment is unsatisfactory.  
Table 2. Treatment Guidelines for Segmental Vitiligo 
Based on previous reports and our experiences, we recently proposed a set of treatment 
guidelines in SV.12 Treatments such as topical corticosteroids and topical calcineurin 
inhibitors, as well as phototherapy, including NB-UVB and targeted phototherapy (e.g., 
excimer laser) are helpful for SV.23,26,30 Available data suggests that combination topical 
treatment and phototherapy is more efficacious in SV than any type of monotherapy.33,34 In 
addition, disease duration in SV is very important to consider to gauge response to medical 
treatment.22,24,30 Thus, as first-line therapy, we recommend the combination of topical 
treatment and phototherapy to be initiated as early as possible. However, our experience 
suggests that phototherapy is not helpful in SV patients with the majority of hairs in lesional 
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skin being white.6 Therefore, in these cases, we recommend first-line treatment be surgery in 
order to avoid delay as well as unnecessary and inefficacious treatment. These guidelines 
will contribute to future definitive treatment guidelines for SV (Table 2). 
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